PharmAbcine Inc.

A208340

KR7208340000

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 18/01/2024 GMT			5-day change	1st Jan Change
2,915 ^KRW	-8.91%		-.--%	-22.27%

01-24	PharmAbcine Inc. Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA®? (Pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors	CI
2023	PharmAbcine Inc. announced that it has received KRW 5.000000492 billion in funding	CI

PharmAbcine Inc. announced that it has received KRW 10 billion in funding from Kiwoom Asset Management Co., Ltd., Hanyang Securities Co. Ltd., NH Investment & Securities Co., Ltd., Investment Arm

April 14, 2022

On April 15, 2022, PharmAbcine Inc. closed the transaction.

Latest news about PharmAbcine Inc.

PharmAbcine Inc. Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA®? (Pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors	01-24	CI
PharmAbcine Inc. announced that it has received KRW 5.000000492 billion in funding	12-25	CI
PharmAbcine Inc. announced that it has received KRW 30.000001149 billion in funding from Hpbiolab Inc.	11-30	CI
Pharmabcine, Inc. Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-Related Macular Degeneration Following Dose Level 1 Safety Data	11-09	CI
PharmAbcine Inc. announced that it expects to receive KRW 5.000000492 billion in funding	25/10/23	CI
PharmAbcine Inc. announced extension to the offering period	06/08/23	CI
Yukon Partners Co., Ltd. acquired a 6.2% stake in PharmAbcine Inc. from Yoo Jin San for KRW 4.4 billion	26/07/23	CI
PharmAbcine Inc. announced that it expects to receive KRW 30.000001149 billion in funding	15/06/23	CI
PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of its Novel TIE2 Agonistic Antibody in nAMD	23/05/23	CI
PharmAbcine Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	15/03/23	CI
Pharmabcine Announces Collaboration Agreement with MSD to Evaluate Anti-Vista Antibody PMC-309 in Combination with Keytruda(R) (Pembrolizumab)	12/12/22	CI
PharmAbcine Inc.(KOSDAQ:A208340) dropped from S&P Global BMI Index	19/09/22	CI
Pharmabcine Inc. Announces the Positive Results from the GLP Toxicology Study of PMC-403, the Company's Novel TIE2-Activating Antibody	26/04/22	CI
PharmAbcine Inc. Announces the Appointment of Quan Dong Nguyen to its Scientific Advisory Board	26/04/22	CI
PharmAbcine Inc. announced that it has received KRW 10 billion in funding from Kiwoom Asset Management Co., Ltd., Hanyang Securities Co. Ltd., NH Investment & Securities Co., Ltd., Investment Arm	14/04/22	CI
PharmAbcine Inc. announced that it expects to receive KRW 10 billion in funding from Kiwoom Asset Management Co., Ltd., Hanyang Securities Co. Ltd., NH Investment & Securities Co., Ltd., Investment Arm and other investors	12/04/22	CI
PharmAbcine Presents Updated Preclinical Data of Its Anti-VISTA Antibody Candidate at AACR 2022	11/04/22	CI
RNAGene Signs a Collaborative Research Agreement with PharmAbcine to Develop Novel Mrna Therapeutics	21/03/22	CI
NuclixBio Inc. Announces a Collaborative Research Agreement with PharmAbcine Inc	14/03/22	CI
PharmAbcine to Present Updated Data of Its Anti-VISTA Antibody Candidate at AACR 2022	08/03/22	CI
PharmAbcine Inc. Announces Last Patient Last Visit in its Phase Ib mTNBC Combination Trial	25/02/22	CI
PharmAbcine Inc. Announces First Patient Enrolled and Dosed in the Phase Ii Clinical Trial for the Treatment of mTNBC	27/12/21	CI
PharmAbcine, Inc. Announces Joint Patent Application with MSD for the Treatment of Cancer	09/09/21	CI
PharmAbcine Receives HREC Clearance for Phase II Trial of Olinvacimab and Pembrolizumab in mTNBC	03/09/21	CI
PharmAbcine Announces Submission of PCT for an Anti-ANG2 Antibody for the Treatment of Ocular Diseases	19/08/21	CI

PharmAbcine Inc. is a Korea-based company mainly engaged in the research and development of biopharmaceuticals. The Company researching and developing antibody therapeutics to provide patients with the antibodies needed to cure the disease. The Companyâs major products include tanibirumab used for cancer treatment, among others. The Company also carries out technology transfer about its pipelines with domestic and overseas pharmaceutical companies.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PHARMABCINE INC.	-22.27%	63.64M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B